Stuttgart

• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with pre … Ended
  2024-517166-42-00 4 2020-05-29 Diffuse large B-cell lymphoma (DLBCL)
• Double-blinded (treatment group unknown to physician and patient), randomised (treatment group allocated by chance) phase II trial on the ef … Ended
  2023-507897-42-00 4 2020-05-12 Prevention of oesophageal strictures in adult patients after endoscopi
• Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070) Ended
  2024-514018-12-00 9 2020-04-06 female and male adult patients with acute myeloid leukemia (AML) at fi
• ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty … Ended
  2024-513947-94-00 4 2020-03-30 locally advanced (stage III) and not suitable for curative treatment,
• A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap … Ended
  2022-501531-16-00 5 2020-01-24 esophageal carcinoma
• CIRCULATE Ended
  2023-506715-18-00 5 2019-12-04 colon cancer stage II, rectal cancer stage II
• A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended
  2022-502886-71-00 5 2019-11-20 Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
• MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse Ended
  2024-513956-14-00 4 2019-09-16 Acute myeloid leukemia
• First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended
  2022-502124-52-00 5 2018-12-18 Advanced epithelial ovarian cancer
• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 5 2018-10-15 Focal segmental glomerulosclerosis (FSGS)
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer
• A Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemothe … Ended
  2023-504209-35-00 5 2018-04-04 Early-Stage Resectable Non-small cell lung cancer (NSCLC)
• A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV … Ended
  2023-508757-75-00 5 2017-09-18 Stage IV Non-Small Cell Lung Cancer (NSCLC)
• A study to test the safety and efficacy of the drug larotrectinib for the treatment of tumors with NTRK-fusion in children Ended
  2022-502668-20-00 9 2017-04-11 Solid tumors harboring NTRK fusion
• Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of … Ended
  2024-512934-14-00 5 2016-11-07 advanced or metastatic adenocarcinoma of the stomach or gastroesophage
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• HD21 Ended
  2024-518022-33-00 5 2016-07-15 Advanced Stage of Hodgkin Lymphoma
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended
  2023-504034-22-00 5 2014-12-18 Chronic Lymphocytic Leukemia (CLL)
• Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem … Ended
  2022-502040-13-00 4 High-risk Myelodysplastic neoplasia

Showing 193–213 of 213 trials